Symbicort Turbuhaler 30/60 Special Clinical Experience Investigation for Long-term Use for Chronic Obstructive Pulmonary Disease (COPD) Patients
Completed
- Conditions
- Chronic Obstructive Pulmonary Disease
- Registration Number
- NCT01713075
- Lead Sponsor
- AstraZeneca
- Brief Summary
The purpose of the investigation is to confirm the safety and efficacy in long-term use of Symbicort Turbuhaler in patients with Chronic obstructive pulmonary disease (COPD) under the post-marketing actual use.
- Detailed Description
Symbicort Turbuhaler 30/60 Special Clinical Experience Investigation for long-term use for COPD patients
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 1183
Inclusion Criteria
- Among patients treated with Symbicort Turbuhaler due to chronic obstructive pulmonary disease(COPD), those who received the drug for the first time.
Exclusion Criteria
Not provided
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Adverse event incidence 1 year
- Secondary Outcome Measures
Name Time Method Clinical questionnaire about chronic obstructive pulmonary disease(CCQ) At baseline, Week 12, Week 26, 1 year
Trial Locations
- Locations (1)
Research Site
🇯🇵Yamanashi, Japan